Product Description
AbobotulinumtoxinA injection is used to relieve the symptoms of cervical dystonia (spasmodic torticollis; uncontrollable tightening of the neck muscles that may cause neck pain and abnormal head positions). It is also used to temporarily smooth frown lines (wrinkles between the eyebrows). AbobotulinumtoxinA injection is used to treat spasticity (muscle stiffness and tightness) of muscles in the arms and legs in adults and children 2 years of age and older. AbobotulinumtoxinA injection is in a class of medications called neurotoxins. It works by blocking the nerve signals that cause uncontrollable tightening and movement of the muscles. (Sourced from: https://medlineplus.gov/druginfo/meds/a609035.html)
Mechanisms of Action: SNAP-25 Inhibitor
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intramuscular
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Brazil | Bulgaria | Chile | Colombia | Croatia | Cyprus | Denmark | Dominican Republic | Egypt | France | Germany | Hong Kong | Hungary | Ireland | Italy | Latvia | Malaysia | Mexico | Morocco | New Zealand | Norway | Philippines | Russia | South Africa | Spain | Taiwan | Thailand | Tunisia | Turkey | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: Dystonia | Muscle Spasticity | Glabellar Reflex
Known Adverse Events: Headache Disorders | Dystonia | Headache | Pain Unspecified | Nasopharyngitis | Pharyngitis | Respiratory Tract Infections | Keratoconjunctivitis Sicca | Glabellar Reflex | Dysphonia | Sinusitis | Edema
Company: Ipsen
Company Location: BOULOGNE BILLANCOURT CEDEX I0 92650
Company CEO: David Loew
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, Czech Republic, France, Georgia, Germany, Italy, Poland, Spain, United Kingdom, United States
Active Clinical Trial Count: 7
Highest Development Phases
Phase 3: Depressive Disorder, Major|Headache Disorders|Migraine Disorders|Musculoskeletal Pain|Pain, Postoperative
Phase 2: Carpal Tunnel Syndrome|Neuropathic Pain
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| C-BEOND | P3 |
Recruiting |
Migraine Disorders |
2026-06-22 |
|
| E-BEOND | P3 |
Recruiting |
Migraine Disorders |
2026-06-22 |
|
| CLIN-52120-464 | P3 |
Unknown Status |
Migraine Disorders |
2025-12-31 |
|
| CLIN-52120-463 | P3 |
Unknown Status |
Migraine Disorders |
2025-12-30 |